CytoDyn annual debt-to-assets ratio
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
CytoDyn's debt-to-assets ratio was 1.89 for fiscal 2026.
View full CytoDyn company overview| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-05-31 | 1.89 | 1.88 | +24097.10% |
| 2025 | 2025-05-31 | 0.01 | −4.06 | −99.81% |
| 2024 | 2024-05-31 | 4.07 | −0.02 | −0.46% |
| 2023 | 2023-05-31 | 4.09 | 2.62 | +178.88% |
| 2022 | 2022-05-31 | 1.47 | 1.14 | +350.76% |
| 2021 | 2021-05-31 | 0.33 | 0.32 | +9126.50% |
| 2020 | 2020-05-31 | 0.00 | −0.17 | −97.95% |
| 2019 | 2019-05-31 | 0.17 | 0.17 | — |
| 2018 | 2018-05-31 | 0.00 | −0.13 | — |
| 2017 | 2017-05-31 | 0.13 | — | — |
| 2015 | 2015-05-31 | 0.01 | −0.27 | −96.65% |
| 2014 | 2014-05-31 | 0.28 | −0.08 | −22.11% |
| 2013 | 2013-05-31 | 0.36 | — | — |
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-05-31 | 1.89 | 1.88 | +24097.10% |
| Q3 2026 | 2026-02-28 | 1.47 | −0.70 | −32.19% |
| Q2 2026 | 2025-11-30 | 4.73 | 2.87 | +154.04% |
| Q1 2026 | 2025-08-31 | 3.25 | 1.63 | +100.18% |
| Q4 2025 | 2025-05-31 | 0.01 | −4.06 | −99.81% |
| Q3 2025 | 2025-02-28 | 2.17 | −2.17 | −49.96% |
| Q2 2025 | 2024-11-30 | 1.86 | −3.14 | −62.78% |
| Q1 2025 | 2024-08-31 | 1.63 | −2.02 | −55.42% |
| Q4 2024 | 2024-05-31 | 4.07 | −0.02 | −0.46% |
| Q3 2024 | 2024-02-29 | 4.34 | 1.21 | +38.46% |
| Q2 2024 | 2023-11-30 | 5.00 | −1.46 | −22.60% |
| Q1 2024 | 2023-08-31 | 3.65 | 2.08 | +132.81% |
| Q4 2023 | 2023-05-31 | 4.09 | 2.62 | +178.88% |
| Q3 2023 | 2023-02-28 | 3.13 | 2.70 | +617.53% |
| Q2 2023 | 2022-11-30 | 6.46 | 6.45 | +105397.58% |
| Q1 2023 | 2022-08-31 | 1.57 | 1.56 | +24043.90% |
| Q4 2022 | 2022-05-31 | 1.47 | 1.14 | +350.76% |
| Q3 2022 | 2022-02-28 | 0.44 | 0.43 | +6338.81% |
| Q2 2022 | 2021-11-30 | 0.01 | 0.00 | +121.74% |
| Q1 2022 | 2021-08-31 | 0.01 | 0.00 | +42.85% |
| Q4 2021 | 2021-05-31 | 0.33 | 0.32 | +9126.50% |
| Q3 2021 | 2021-02-28 | 0.01 | −0.10 | −93.61% |
| Q2 2021 | 2020-11-30 | 0.00 | −0.28 | −99.04% |
| Q1 2021 | 2020-08-31 | 0.00 | −0.27 | −98.37% |
| Q4 2020 | 2020-05-31 | 0.00 | −0.17 | −97.95% |
| Q3 2020 | 2020-02-29 | 0.11 | −0.00 | −4.47% |
| Q2 2020 | 2019-11-30 | 0.29 | 0.01 | +4.51% |
| Q1 2020 | 2019-08-31 | 0.28 | −0.28 | −50.54% |
| Q4 2019 | 2019-05-31 | 0.17 | 0.17 | — |
| Q3 2019 | 2019-02-28 | 0.11 | — | — |
| Q2 2019 | 2018-11-30 | 0.27 | −0.56 | −66.96% |
| Q1 2019 | 2018-08-31 | 0.56 | −0.17 | −23.41% |
| Q4 2018 | 2018-05-31 | 0.00 | −0.13 | — |
| Q2 2018 | 2017-11-30 | 0.83 | — | — |
| Q1 2018 | 2017-08-31 | 0.73 | — | — |
| Q4 2017 | 2017-05-31 | 0.13 | — | — |
| Q1 2016 | 2015-08-31 | 0.49 | 0.00 | +1.02% |
| Q4 2015 | 2015-05-31 | 0.01 | −0.27 | −96.65% |
| Q3 2015 | 2015-02-28 | 0.53 | 0.32 | +160.08% |
| Q2 2015 | 2014-11-30 | 0.39 | 0.25 | +175.77% |
| Q1 2015 | 2014-08-31 | 0.48 | 0.03 | +6.51% |
| Q4 2014 | 2014-05-31 | 0.28 | −0.08 | −22.11% |
| Q3 2014 | 2014-02-28 | 0.20 | — | — |
| Q2 2014 | 2013-11-30 | 0.14 | — | — |
| Q1 2014 | 2013-08-31 | 0.45 | — | — |
| Q4 2013 | 2013-05-31 | 0.36 | — | — |
Over the last five fiscal years, CytoDyn's debt-to-assets ratio increased from 0.33 to 1.89, a change of 1.57. The latest reported quarter, Q4 2026, shows 1.89.
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CytoDyn source filings ↗